Seres Therapeutics (MCRB) Misses Q4 EPS by 61c

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• UBS Reiterates Buy Rating on KB Home (KBH) Amid Transition Back to Built-to-Order
• Ladybug Resource Group updates M&A program, holds early financing talks
• UBS starts CoreWeave at Buy in non-consensus call, sees 40% upside